Structure Therapeutics
GPCR
121 hedge funds and large institutions have $1.74B invested in Structure Therapeutics in 2023 Q4 according to their latest regulatory filings, with 54 funds opening new positions, 37 increasing their positions, 24 reducing their positions, and 17 closing their positions.
218% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 17
190% more call options, than puts
Call options by funds: $70.3M | Put options by funds: $24.2M
54% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 24
44% more funds holding
Funds holding: 84 → 121 (+37)
6% more capital invested
Capital invested by funds: $1.64B → $1.74B (+$93M)
0.07% more ownership
Funds ownership: 30.53% → 30.6% (+0.07%)
27% less funds holding in top 10
Funds holding in top 10: 11 → 8 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$201M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$140M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$76.4M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$66.3M |
| 5 |
Capital International Investors
Los Angeles,
California
|
+$48.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$92.6M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$53.7M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$53.3M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$47.8M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$37.7M |
GPCR Hedge Fund Activity: Q4 2023 in Review
121 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Structure Therapeutics (GPCR) for Q4 2023, worth a combined $1.74B — up 5.7% from $1.64B a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new GPCR positions and 17 closed out — a net gain of 37 holders — while 37 added to existing stakes and 24 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $201M. The largest seller was Deep Track Capital, cutting an estimated $92.6M.
- 121 institutional investors held Structure Therapeutics (GPCR) as of Q4 2023, up from 84 in Q3 2023.
- Funds reported $1.74B of Structure Therapeutics stock for Q4 2023, up 5.7% quarter-over-quarter.
- 54 funds opened new Structure Therapeutics positions in Q4 2023 and 17 closed out, a net change of +37 holders.
- The largest Structure Therapeutics buyer in Q4 2023 was Wellington Management Group, an estimated $201M added.
- The largest Structure Therapeutics seller in Q4 2023 was Deep Track Capital, an estimated $92.6M sold.
Based on aggregated 13F filings for Q4 2023.